|BioShares Biotechnology Products -- USA Etf|| |
USD 41.61 0.53 1.29%
The organization shows Beta (market volatility) of 1.5094 which signifies that as market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, BioShares Biotechnology will likely underperform.. Although it is extremely important to respect BioShares Biotechnology
historical returns, it is better to be realistic regarding the information on equity current trending patterns. The philosophy towards foreseeing future performance of any etf is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators
. By analyzing BioShares Biotechnology technical indicators
you can presently evaluate if the expected return of 0.2386% will be sustainable into the future.
BioShares Biotechnology Relative Risk vs. Return Landscape
If you would invest 3,980
in BioShares Biotechnology Products on December 17, 2017
and sell it today you would earn a total of 180.62
from holding BioShares Biotechnology Products or generate 4.54%
return on investment over 30
days. BioShares Biotechnology Products is generating 0.2386% of daily returns assuming volatility of 0.9996% on return distribution over 30 days investment horizon. In other words, 9% of equities are less volatile than the company and above 96% of equities are expected to generate higher returns over the next 30 days.
Daily Expected Return (%)
Considering 30-days investment horizon, BioShares Biotechnology Products is expected to generate 2.6 times more return on investment than the market. However, the company is 2.6 times more volatile than its market benchmark. It trades about 0.24 of its potential returns per unit of risk. The DOW is currently generating roughly 0.55 per unit of risk.
Based on latest financial disclosure the price to book indicator of BioShares Biotechnology Products is roughly 1.66 times. This is 2.92% lower than that of the Bio Shares family, and 2.64% lower than that of Health
category, The Price to Book for all etfs is 71.13% lower than the firm.
| || BioShares Biotechnology Comparables |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
BioShares Biotechnology Daily Price Distribution
The median price of BioShares Biotechnology for the period between Sun, Dec 17, 2017 and Tue, Jan 16, 2018 is 40.77 with a coefficient of variation of 1.71. The daily time series for the period is distributed with a sample standard deviation of 0.69, arithmetic mean of 40.54, and mean deviation of 0.58. The Etf did not receive any noticable media coverage during the period.